Cargando…
免疫检查点抑制剂在EGFR突变型晚期非小细胞肺癌中的应用
In recent years, immune checkpoint inhibitors (ICIs) have greatly improved the survival rate of non-small cell lung cancer (NSCLC) patients without driver mutation. Compared with wild-type tumors, tumors with epidermal growth factor receptor (EGFR) mutations have greater heterogeneity in immune micr...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9549429/ https://www.ncbi.nlm.nih.gov/pubmed/36172732 http://dx.doi.org/10.3779/j.issn.1009-3419.2022.102.32 |